U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment: description was created based on several sources, including https://www.accessdata.fda.gov/cdrh_docs/pdf9/P090031c.pdf | https://www.ncbi.nlm.nih.gov/pubmed/17773757 | https://www.ncbi.nlm.nih.gov/pubmed/10903951 | https://www.ncbi.nlm.nih.gov/pubmed/19415575 | https://www.ncbi.nlm.nih.gov/pubmed/10903951 | https://www.ncbi.nlm.nih.gov/pubmed/16049255

Hyaluronic acid (HA) is a high molecular weight biopolysacharide, discovered in 1934, by Karl Meyer and his assistant, John Palmer in the vitreous of bovine eyes. Hyaluronic acid is a naturally occurring biopolymer, which has important biological functions in bacteria and higher animals including humans. It is found in most connective tissues and is particularly concentrated in synovial fluid, the vitreous fluid of the eye, umbilical cords and chicken combs. It is naturally synthesized by a class of integral membrane proteins called hyaluronan synthases, and degraded by a family of enzymes called hyaluronidases. Hyaluronan synthase enzymes synthesize large, linear polymers of the repeating disaccharide structure of hyaluronan by alternating addition of glucuronic acid and N-acetylglucosamine to the growing chain using their activated nucle¬otide sugars (UDP – glucuronic acid and UDP-N-acetlyglucosamine) as substrates. The number of repeat disaccharides in a completed hyaluronan molecule can reach 10 000 or more, a molecular mass of ~4 million daltons (each disaccharide is ~400 daltons). The average length of a disaccharide is ~1 nm. Thus, a hyaluronan molecule of 10 000 repeats could ex¬tend 10 μm if stretched from end to end, a length approximately equal to the diameter of a human erythrocyte. Although the predominant mechanism of HA is unknown, in vivo, in vitro, and clinical studies demonstrate various physiological effects of exogenous HA. Hyaluronic acid possesses a number of protective physiochemical functions that may provide some additional chondroprotective effects in vivo and may explain its longer term effects on articular cartilage. Hyaluronic acid can reduce nerve impulses and nerve sensitivity associated with pain. In experimental osteoarthritis, this glycosaminoglycan has protective effects on cartilage. Exogenous HA enhances chondrocyte HA and proteoglycan synthesis, reduces the production and activity of proinflammatory mediators and matrix metalloproteinases, and alters the behavior of immune cells. In addition to its function as a passive structural molecule, hyaluronan also acts as a signaling molecule by interacting with cell surface receptors and regulating cell proliferation, migration, and differentiation. Hyaluronan is essential for embryogenesis and is likely also important in tumorigenesis. HA plays several important organizational roles in the extracellular matrix (ECM) by binding with cells and other components through specific and nonspecific interactions. Hyaluronan-binding pro¬teins are constituents of the extracellular matrix, and stabilize its integrity. Hyaluronan receptors are involved in cellular signal transduction; one receptor family includes the binding proteins aggrecan, link protein, versican and neurocan and the receptors CD44, TSG6, GHAP and LYVE-1. The chondroprotective effects of hyaluronic acid, e.g., that it stimulates the production of tissue in¬hibitors of matrix metalloproteineses (TIMP-1) by chondrocytes, inhibits neutrophil-mediated cartilage degradation and attenuates IL-1 induced matrix de¬generation and chondrocyte cytotoxicity have been observed in vitro. Articular chondrocytes cultured in the presence of HA have a significantly greater rate of DNA proliferation and ex¬tracellular matrix production, compared with chon¬drocytes cultured without HA.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P98066
Gene ID: 7130.0
Gene Symbol: TNFAIP6
Target Organism: Homo sapiens (Human)
0.5 µM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Monovisc

Approved Use

MONOVISC™ is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics (e.g., acetaminophen).

Launch Date

1.39328645E12
PubMed

PubMed

TitleDatePubMed
THE NATURE OF THE MUCO-POLYSACCHARIDE OF SYNOVIAL FLUID.
1938 Aug 5
Patents

Patents

Sample Use Guides

Monovisc™ (Hyaluronic acid, Hyaluronan) is injected into the knee joint and is administered as a single intra-articular injection. Each single intra-articular injection of Monovisc™ contains 88 mg of Hyaluronan.
Route of Administration: Other
Bovine articular chondrocytes were isolated and seeded into alginate constructs. The alginate gels were made to four different concentrations of hyaluronic acid: 0.1, 1.0, 2.0, and 3.0 mg/mL. The control specimens contained alginate that was free from hyaluronic acid. The alginate/chondrocyte/hyaluronic acid suspensions were then gently expressed through a 22-gauge needle attached to a 5 mL syringe into a 100 mm CaCl2 solution in a sterile Petri dish and each drop polymerised to form an alginate bead containing approximately 100 000 chondrocytes. Twenty minutes of incubation was allowed for further polymerisation. The newly-formed beads were then washed twice in EBSS to remove excess CaCl2. Five sets of beads containing hyaluronic acid at the four different concentrations, and a control set of beads containing chondrocytes without hyaluronic acid, were formed and were used for the culture experiments. Each set of alginate beads was then transferred into sterile 24-well culture plates, with eight randomly chosen beads placed in each well containing 1 mL of culture medium supplemented with hyaluronic acid at the same concentration as that in the respective alginate beads. The hydrogel constructs were cultured for a period of 14 days in the humidified atmosphere of a standard incubator at 37°C and 5% CO2. The culture medium was replaced by fresh culture medium every three days. Six replicates of eight alginate beads were removed randomly from each of the five cultures at 0, 3, 6, 9, and 14 days for analysis.
Substance Class Polymer
Created
by admin
on Sat Dec 16 09:15:01 UTC 2023
Edited
by admin
on Sat Dec 16 09:15:01 UTC 2023
Record UNII
S270N0TRQY
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HYALURONIC ACID
HSDB   INCI   MI   VANDF   WHO-DD  
INCI  
Official Name English
HYALURONATE
Common Name English
Hyaluronic acid [WHO-DD]
Common Name English
HYALURONIC ACID [VANDF]
Common Name English
HYALURONIC ACID [MI]
Common Name English
HYALURONIC ACID [HSDB]
Common Name English
HYALURONIC ACID (STREPTOCOCCUS EQUI)
Common Name English
HYALURONIC ACID [INCI]
Common Name English
HYALURONAN
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C28153
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
FDA ORPHAN DRUG 550716
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-ATC S01KA51
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-VATC QD03AX05
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-VATC QR01AX09
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
FDA ORPHAN DRUG 153501
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-VATC QS01KA01
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-ATC S01KA01
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-VATC QM09AX01
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-ATC R01AX09
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-ATC M09AX01
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
DSLD 467 (Number of products:627)
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-ATC D03AX05
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
WHO-VATC QS01KA51
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
Code System Code Type Description
MERCK INDEX
m6066
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY Merck Index
EVMPD
SUB14126MIG
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
FDA UNII
S270N0TRQY
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
MESH
D006820
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
CHEBI
132153
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
RXCUI
27306
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
ALTERNATIVE
RXCUI
5463
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
ECHA (EC/EINECS)
232-678-0
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
NCI_THESAURUS
C549
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
RXCUI
62372
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
ALTERNATIVE
HSDB
9004-61-9
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
DRUG CENTRAL
3957
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
CAS
9004-61-9
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
GENERIC (FAMILY)
DRUG BANK
DB08818
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
SMS_ID
100000092136
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
MESH
C049816
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
RXCUI
258347
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
ALTERNATIVE
WIKIPEDIA
HYALURONAN
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
ChEMBL
CHEMBL2110674
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
DAILYMED
S270N0TRQY
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
CHEBI
16336
Created by admin on Sat Dec 16 09:15:01 UTC 2023 , Edited by admin on Sat Dec 16 09:15:01 UTC 2023
PRIMARY
Display Structure of HYALURONIC ACID
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL